Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients

Makoto Nakamuta, Kazuhiro Kotoh, Munechika Enjoji, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Yuichi Tanabe, Jun Hayashi

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Background: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to the reduction of HBV replication itself, rather than to cessation of hepatitis. In order to confirm this hypothesis, in this study we evaluated factors which correlated with the increase in serum albumin levels. Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. We analyzed the correlation between the increase in serum albumin levels at month 12 after starting treatment (Δ-albumin) and various pretreatment variables. We also analyzed the correlation between Δ-albumin and the reduction in serum levels of HBV-DNA (Δ-HBV-DNA) or alanine aminotransferase (Δ-ALT) at month 12. Results: The average Δ-albumin was 0.38 g/dL and only serum HBV-DNA levels before treatment correlated significantly with Δ-albumin. We also analyzed the correlation in patients whose alanine aminotransferase levels were normalized after 12 months so that the possible influence of breakthrough hepatitis could be excluded. Even among this subgroup of patients, there was no significant correlation between Δ-albumin and either pretreatment alanine aminotransferase levels or Δ-ALT. In contrast, in patients whose serum HBV-DNA was undetectable at month 12, we found a significant correlation between Δ-albumin and both pretreatment serum HBV-DNA levels and Δ-HBV-DNA. Conclusion: Our results demonstrated that albumin levels are associated with pretreatment HBV-DNA but not with alanine aminotransferase levels.

元の言語英語
記事番号3
ジャーナルComparative Hepatology
6
DOI
出版物ステータス出版済み - 5 1 2007

Fingerprint

Lamivudine
Hepatitis B virus
Serum Albumin
Albumins
DNA
Alanine Transaminase
Serum
Hepatitis
Hypoalbuminemia
Virus Diseases
Virus Replication
Liver Cirrhosis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology

これを引用

Nakamuta, M., Kotoh, K., Enjoji, M., Kajiwara, E., Shimono, J., Masumoto, A., ... Hayashi, J. (2007). Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comparative Hepatology, 6, [3]. https://doi.org/10.1186/1476-5926-6-3

Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. / Nakamuta, Makoto; Kotoh, Kazuhiro; Enjoji, Munechika; Kajiwara, Eiji; Shimono, Junya; Masumoto, Akihide; Maruyama, Toshihiro; Furusyo, Norihiro; Nomura, Hideyuki; Sakai, Hironori; Takahashi, Kazuhiro; Azuma, Koichi; Shimoda, Shinji; Tanabe, Yuichi; Hayashi, Jun.

:: Comparative Hepatology, 巻 6, 3, 01.05.2007.

研究成果: ジャーナルへの寄稿記事

Nakamuta, M, Kotoh, K, Enjoji, M, Kajiwara, E, Shimono, J, Masumoto, A, Maruyama, T, Furusyo, N, Nomura, H, Sakai, H, Takahashi, K, Azuma, K, Shimoda, S, Tanabe, Y & Hayashi, J 2007, 'Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients', Comparative Hepatology, 巻. 6, 3. https://doi.org/10.1186/1476-5926-6-3
Nakamuta, Makoto ; Kotoh, Kazuhiro ; Enjoji, Munechika ; Kajiwara, Eiji ; Shimono, Junya ; Masumoto, Akihide ; Maruyama, Toshihiro ; Furusyo, Norihiro ; Nomura, Hideyuki ; Sakai, Hironori ; Takahashi, Kazuhiro ; Azuma, Koichi ; Shimoda, Shinji ; Tanabe, Yuichi ; Hayashi, Jun. / Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. :: Comparative Hepatology. 2007 ; 巻 6.
@article{082f6d6ed73642ecb9534181fec6464a,
title = "Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients",
abstract = "Background: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to the reduction of HBV replication itself, rather than to cessation of hepatitis. In order to confirm this hypothesis, in this study we evaluated factors which correlated with the increase in serum albumin levels. Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. We analyzed the correlation between the increase in serum albumin levels at month 12 after starting treatment (Δ-albumin) and various pretreatment variables. We also analyzed the correlation between Δ-albumin and the reduction in serum levels of HBV-DNA (Δ-HBV-DNA) or alanine aminotransferase (Δ-ALT) at month 12. Results: The average Δ-albumin was 0.38 g/dL and only serum HBV-DNA levels before treatment correlated significantly with Δ-albumin. We also analyzed the correlation in patients whose alanine aminotransferase levels were normalized after 12 months so that the possible influence of breakthrough hepatitis could be excluded. Even among this subgroup of patients, there was no significant correlation between Δ-albumin and either pretreatment alanine aminotransferase levels or Δ-ALT. In contrast, in patients whose serum HBV-DNA was undetectable at month 12, we found a significant correlation between Δ-albumin and both pretreatment serum HBV-DNA levels and Δ-HBV-DNA. Conclusion: Our results demonstrated that albumin levels are associated with pretreatment HBV-DNA but not with alanine aminotransferase levels.",
author = "Makoto Nakamuta and Kazuhiro Kotoh and Munechika Enjoji and Eiji Kajiwara and Junya Shimono and Akihide Masumoto and Toshihiro Maruyama and Norihiro Furusyo and Hideyuki Nomura and Hironori Sakai and Kazuhiro Takahashi and Koichi Azuma and Shinji Shimoda and Yuichi Tanabe and Jun Hayashi",
year = "2007",
month = "5",
day = "1",
doi = "10.1186/1476-5926-6-3",
language = "English",
volume = "6",
journal = "Comparative Hepatology",
issn = "1476-5926",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Enjoji, Munechika

AU - Kajiwara, Eiji

AU - Shimono, Junya

AU - Masumoto, Akihide

AU - Maruyama, Toshihiro

AU - Furusyo, Norihiro

AU - Nomura, Hideyuki

AU - Sakai, Hironori

AU - Takahashi, Kazuhiro

AU - Azuma, Koichi

AU - Shimoda, Shinji

AU - Tanabe, Yuichi

AU - Hayashi, Jun

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to the reduction of HBV replication itself, rather than to cessation of hepatitis. In order to confirm this hypothesis, in this study we evaluated factors which correlated with the increase in serum albumin levels. Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. We analyzed the correlation between the increase in serum albumin levels at month 12 after starting treatment (Δ-albumin) and various pretreatment variables. We also analyzed the correlation between Δ-albumin and the reduction in serum levels of HBV-DNA (Δ-HBV-DNA) or alanine aminotransferase (Δ-ALT) at month 12. Results: The average Δ-albumin was 0.38 g/dL and only serum HBV-DNA levels before treatment correlated significantly with Δ-albumin. We also analyzed the correlation in patients whose alanine aminotransferase levels were normalized after 12 months so that the possible influence of breakthrough hepatitis could be excluded. Even among this subgroup of patients, there was no significant correlation between Δ-albumin and either pretreatment alanine aminotransferase levels or Δ-ALT. In contrast, in patients whose serum HBV-DNA was undetectable at month 12, we found a significant correlation between Δ-albumin and both pretreatment serum HBV-DNA levels and Δ-HBV-DNA. Conclusion: Our results demonstrated that albumin levels are associated with pretreatment HBV-DNA but not with alanine aminotransferase levels.

AB - Background: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to the reduction of HBV replication itself, rather than to cessation of hepatitis. In order to confirm this hypothesis, in this study we evaluated factors which correlated with the increase in serum albumin levels. Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. We analyzed the correlation between the increase in serum albumin levels at month 12 after starting treatment (Δ-albumin) and various pretreatment variables. We also analyzed the correlation between Δ-albumin and the reduction in serum levels of HBV-DNA (Δ-HBV-DNA) or alanine aminotransferase (Δ-ALT) at month 12. Results: The average Δ-albumin was 0.38 g/dL and only serum HBV-DNA levels before treatment correlated significantly with Δ-albumin. We also analyzed the correlation in patients whose alanine aminotransferase levels were normalized after 12 months so that the possible influence of breakthrough hepatitis could be excluded. Even among this subgroup of patients, there was no significant correlation between Δ-albumin and either pretreatment alanine aminotransferase levels or Δ-ALT. In contrast, in patients whose serum HBV-DNA was undetectable at month 12, we found a significant correlation between Δ-albumin and both pretreatment serum HBV-DNA levels and Δ-HBV-DNA. Conclusion: Our results demonstrated that albumin levels are associated with pretreatment HBV-DNA but not with alanine aminotransferase levels.

UR - http://www.scopus.com/inward/record.url?scp=34249898381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249898381&partnerID=8YFLogxK

U2 - 10.1186/1476-5926-6-3

DO - 10.1186/1476-5926-6-3

M3 - Article

AN - SCOPUS:34249898381

VL - 6

JO - Comparative Hepatology

JF - Comparative Hepatology

SN - 1476-5926

M1 - 3

ER -